ABCG2 and cancer: In this study using P388 murine leukemia model we investigate whether SP1049C therapy can 1) decrease tumorigenicity and aggressiveness of cancer cells, 2) prevent overexpression of BCRP and activation of Wnt signaling pathway generally associated with cancer aggressiveness and poor prognosis, 3) affect the DNA methylation patterns indicative of epigenetic gene regulation, and 4) deplete subpopulations of cells with various CSC biomarkers.